Korsana Biosciences, Inc. (KRSA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of KRSA were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No KRSA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KRSA short interest
Low short interest. 3.6% of KRSA shares are sold short: about 1 share in 28. Over the last 4 reports the number of shares short went up 3668%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 167,367 KRSA shares were sold short, 3.6% of the shares outstanding, up 603.1% from the report before. At the average daily volume of 178,210 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 167,367 | 3.58% | +603% | 178,210 | 1.0 |
| Oct 15, 2026 | 23,804 | 0.51% | +106% | 97,778 | 1.0 |
| Sep 30, 2026 | 11,552 | 0.25% | +160% | 83,653 | 1.0 |
| Sep 15, 2026 | 4,442 | 0.09% | -75% | 46,593 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Korsana Biosciences company events
Korsana Biosciences filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (control). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 11, 2026ControlChanges in Control of the Registrant. Filing
- Aug 27, 2026AnnouncementAt the Shareholder Meeting on August 26, 2026, Cyclerion’s shareholders approved the Reverse Stock Split Proposal. Filing
- Aug 25, 2026AnnouncementThe board of directors of Cyclerion Therapeutics, Inc. fixed the close of business on September 4, 2026 as the record date for the Company’s previously announced distribution of contingent value rights to holders of record of the Company’s common stock and the Company’s Series A Preferred Stock, in… Filing
- Apr 1, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
- Feb 17, 2026AnnouncementShared information with investors. Filing
- Jan 6, 2026AgreementCyclerion Therapeutics, Inc. and the Medsteer, SAS entered into a Collaboration and Option Agreement pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to… Filing
- Dec 1, 2025AnnouncementAkebia Therapeutics, Inc. publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis using Praliciguat, an oral soluble guanylate cyclase licensed to Akebia by Cyclerion Therapeutics, Inc. (Cyclerion”). Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Korsana Biosciences financials
Famous investors that hold KRSA
3 of the 50 well-known investors we track reported holding KRSA in their latest 13F filing. The largest position is Stanley Druckenmiller's, worth $8.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 278,561 | $8.9M | 0.2% | New |
| Israel Englander · Millennium Management | Q3 2026 | 23,320 | $746K | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 7,519 | $241K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 16 filings named KRSA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G | 5.2% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.7% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G | 10.0% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G | 5.2% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G | 10.0% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.7% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 0.1% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 1.3% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 0.1% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 1.3% |
| Nov 10, 2026 | JPMORGAN CHASE & CO. | 13G | 5.9% |
| Nov 10, 2026 | JPMORGAN CHASE & CO. | 13G | 5.9% |
| Oct 15, 2026 | J. Wood Capital Advisors LLC | 13G/A | 0.1% |
| Oct 15, 2026 | J. Wood Capital Advisors LLC | 13G/A | 0.1% |
| Oct 7, 2026 | FMR LLC | 13G/A | 6.9% |
| Oct 7, 2026 | FMR LLC | 13G/A | 6.9% |
Questions about Korsana Biosciences, Inc. (KRSA) stock
Are KRSA insiders buying or selling?
No KRSA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in KRSA?
As of Oct 30, 2026, 167,367 KRSA shares were sold short, 3.6% of the shares outstanding, up 603.1% from the report before. At the average daily volume of 178,210 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold KRSA?
3 of the 50 well-known investors we track reported KRSA in their latest 13F filing, including Stanley Druckenmiller, Israel Englander, Ken Griffin. The largest position is worth $8.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.